3 Days
Source:
صراحة
_1777294237270_124456903.png&w=48&q=75){kind=small}
FDA Approves Aicervo for Biliary Disease
The General Authority for Food and Drug approved the registration of the product "AIKERVO" for the treatment of primary biliary cholangitis in adults who have not responded to or cannot tolerate other treatments. The product works by improving bile flow and reducing inflammation and liver fibrosis through activation of receptors in liver cells. It has shown effective results after 52 weeks of treatment, with common side effects including abdominal pain and gastrointestinal disturbances.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)